Abstract
The global pandemic caused by SARS-CoV-2 is a major public health problem. Virus entry occurs via binding to ACE2. Five SARS-CoV-2 variants of concern (VOCs) were reported so far, all having immune escape characteristics. Infection with the current VOC Omicron was noticed in immunized and recovered individuals; therefore, the development of new treatments against VOC infections is urgently needed. Most approved mAbs treatments against SARS-CoV-2 are directed against the spike protein of the original virus and are therefore inefficient against Omicron. Here, we report on the generation of hACE2.16, an anti-ACE2 antibody that recognizes and blocks ACE2-RBD binding without affecting ACE2 enzymatic activity. We demonstrate that hACE2.16 binding to ACE2 does not affect its surface expression and that hACE2.16 blocks infection and virus production of various VOCs including Omicron BA.1 and BA.2. hACE2.16 might, therefore, be an efficient treatment against all VOCs, the current and probably also future ones.
Original language | English |
---|---|
Article number | 104935 |
Journal | iScience |
Volume | 25 |
Issue number | 9 |
DOIs | |
State | Published - 16 Sep 2022 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2022 The Author(s)
Funding
This work was supported by the following grants awarded to O.M.: the Israel Innovation Authority Kamin grant 62615, the German-Israeli Foundation for Scientific Research and Development grant 1412-414.13/2017, the ICRF professorship grant, the ISF Israel-China grant 2554/18, the MOST-DKFZ grant 3-14931, and the Ministry of Science and Technology grant 3-14764, by Integra Holdings LTD, By the Rothschild Foundation and by the Israel Science Foundation Moked grant 442-18. Graphical abstract was created with BioRender.com. Conceptualization, O.M. and S.J.; Methodology, O.M. S.J. M.M. and D.W.; Investigation, A.E.C. I.B. P.K.B. N.A. L.K. O.A. I.K. and L.T.; Visualization, O.M. and A.E.C.; Funding acquisition, O.M. and S.J.; Project administration, O.M.; Supervision, O.M.; Writing – original draft, O.M. and A.E.C.; Writing – review & editing, O.M. and A.E.C. A patent application has been submitted by Yissum, the Hebrew University Tech Transfer Company, based on these results. This work was supported by the following grants awarded to O.M.: the Israel Innovation Authority Kamin grant 62615 , the German-Israeli Foundation for Scientific Research and Development grant 1412-414.13/2017 , the ICRF professorship grant, the ISF Israel-China grant 2554/18 , the MOST- DKFZ grant 3-14931 , and the Ministry of Science and Technology grant 3-14764 , by Integra Holdings LTD, By the Rothschild Foundation and by the Israel Science Foundation Moked grant 442-18 . Graphical abstract was created with BioRender.com .
Funders | Funder number |
---|---|
ISF Israel-China | 2554/18 |
Integra Holdings LTD | |
Israel Innovation Authority Kamin | 62615 |
Israel Science Foundation Moked | 442-18 |
MOST-DKFZ | |
Rothschild Foundation | |
Israel Cancer Research Fund | |
German-Israeli Foundation for Scientific Research and Development | 1412-414.13/2017 |
Ministry of Science, Technology and Space | 3-14931 |
Hebrew University of Jerusalem | |
Ministry of science and technology, Israel | 3-14764 |
Keywords
- Health sciences
- immune response
- immunology
- virology